|
US8097648B2
(en)
*
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
US6653341B1
(en)
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
US6214865B1
(en)
*
|
1998-06-17 |
2001-04-10 |
Eisai Co., Ltd. |
Macrocyclic analogs and methods of their use and preparation
|
|
DE10037310A1
(de)
|
2000-07-28 |
2002-02-07 |
Asta Medica Ag |
Neue Indolderivate und deren Verwendung als Arzneimittel
|
|
EP1531846A4
(en)
*
|
2002-02-27 |
2006-04-19 |
Us Gov Health & Human Serv |
Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
|
|
AU2003228354B8
(en)
|
2002-03-22 |
2010-03-04 |
Eisai R&D Management Co., Ltd. |
Hemiasterlin derivatives and uses thereof in the treatment of cancer
|
|
US20050075395A1
(en)
*
|
2003-05-28 |
2005-04-07 |
Gary Gordon |
Continuous dosing regimen
|
|
EP1644008B1
(en)
*
|
2003-05-29 |
2011-12-21 |
Abbott Laboratories |
Continuous dosing regimen with abt-751
|
|
EP1653953A4
(en)
*
|
2003-07-29 |
2010-05-05 |
Eisai R&D Man Co Ltd |
METHOD AND DEVICES FOR THE MEDICINAL PRODUCTION
|
|
EP2522663B1
(en)
|
2004-06-03 |
2015-04-01 |
Eisai R&D Management Co., Ltd. |
Intermediates for the preparation of halichondrin B
|
|
CA2822994C
(en)
*
|
2004-06-03 |
2016-09-27 |
Eisai R&D Management Co., Ltd. |
Intermediates for the preparation of analogs of halichondrin b
|
|
US20060045846A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Horstmann Thomas E |
Reagents and methods for labeling terminal olefins
|
|
EP1831697A4
(en)
*
|
2004-12-09 |
2011-01-26 |
Eisai R&D Man Co Ltd |
SEARCH FOR TUBULINISOTYPES IN CANCER THERAPY USING HALICHONDRIN B ANALOG
|
|
RU2489437C2
(ru)
*
|
2007-10-03 |
2013-08-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Промежуточные соединения и способы синтеза аналогов галихондрина в
|
|
CN105801599A
(zh)
*
|
2008-04-04 |
2016-07-27 |
卫材R&D管理有限公司 |
软海绵素b类似物
|
|
EP2415464B1
(en)
|
2009-03-30 |
2017-05-10 |
Eisai R&D Management Co., Ltd. |
Method for producing liposome composition
|
|
RU2476216C1
(ru)
*
|
2009-03-30 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Липосомальная композиция
|
|
ES2593027T3
(es)
|
2009-03-30 |
2016-12-05 |
Eisai R&D Management Co., Ltd. |
Composición liposomal
|
|
EP2420504B1
(en)
*
|
2009-04-14 |
2014-01-15 |
Nissan Chemical Industries, Ltd. |
Method for producing tetrahydropyran compound and intermediate thereof
|
|
DK2468281T3
(en)
|
2009-08-19 |
2016-03-21 |
Eisai R&D Man Co Ltd |
Quinolinderivatholdig pharmaceutical composition
|
|
WO2011094339A1
(en)
|
2010-01-26 |
2011-08-04 |
Eisai R&D Management Co., Ltd. |
Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
|
|
EP2686441B1
(en)
|
2011-03-18 |
2019-05-08 |
Eisai R&D Management Co., Ltd. |
Methods and uses for predicting response to eribulin
|
|
WO2012147900A1
(en)
|
2011-04-28 |
2012-11-01 |
Eisai R&D Management Co., Ltd. |
Microreactor process for halichondrin b analog synthesis
|
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
|
EP2785687B1
(en)
|
2011-11-30 |
2019-02-20 |
Sandoz AG |
Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
|
|
CN104024237B
(zh)
|
2011-12-16 |
2016-02-24 |
阿方拉研究股份有限公司 |
用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体
|
|
CN104080793B
(zh)
*
|
2011-12-29 |
2017-09-19 |
阿方拉研究股份有限公司 |
2‑((2s,3s,4r,5r)‑5‑((s)‑3‑氨基‑2‑羟基丙‑1‑基)‑4‑甲氧基‑3‑(苯磺酰甲基)四氢呋喃‑2‑基)乙醛衍生物以及它们的制备方法
|
|
WO2013142999A1
(en)
*
|
2012-03-30 |
2013-10-03 |
Alphora Research Inc. |
Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
|
|
MX2015007185A
(es)
|
2012-12-04 |
2017-09-05 |
Eisai R&D Man Co Ltd |
Uso de eribulina en el tratamiento de cancer de pecho.
|
|
AR096238A1
(es)
|
2013-05-15 |
2015-12-16 |
Alphora Res Inc |
Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
|
|
KR102265952B1
(ko)
|
2013-06-26 |
2021-06-16 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
|
|
CA2916537C
(en)
*
|
2013-07-03 |
2021-07-27 |
Alphora Research Inc. |
Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
|
|
CN103483352A
(zh)
*
|
2013-10-18 |
2014-01-01 |
李友香 |
抗肿瘤的药用原料药
|
|
EP3689881B1
(en)
|
2013-11-04 |
2022-01-12 |
Eisai R&D Management Co., Ltd. |
Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
|
|
MX384292B
(es)
*
|
2013-12-06 |
2025-03-14 |
Eisai R&D Man Co Ltd |
Metodos utiles en la sintesis de analogos de halicondrina b.
|
|
CN104860978A
(zh)
*
|
2014-02-20 |
2015-08-26 |
正大天晴药业集团股份有限公司 |
软海绵素b类似物的合成中间体
|
|
TW201617326A
(zh)
*
|
2014-03-06 |
2016-05-16 |
Ａｌｐｈｏｒａ研發股份有限公司 |
（ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
|
|
RU2699545C2
(ru)
*
|
2014-05-28 |
2019-09-06 |
ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД |
Применение эрибулина в лечении рака
|
|
US10556910B2
(en)
*
|
2014-06-30 |
2020-02-11 |
President And Fellows Of Harvard College |
Synthesis of halichondrin analogs and uses thereof
|
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
|
WO2016038624A1
(en)
|
2014-09-09 |
2016-03-17 |
Cipla Limited |
"process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
|
|
CN105713031B
(zh)
*
|
2014-12-05 |
2021-05-07 |
正大天晴药业集团股份有限公司 |
一种用于制备艾日布林的中间体及其制备方法
|
|
AU2016224583B2
(en)
|
2015-02-25 |
2021-06-03 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
|
CA2978311A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating cancer
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
US10344038B2
(en)
|
2015-04-30 |
2019-07-09 |
President And Fellows Of Harvard College |
Chromium-mediated coupling and application to the synthesis of halichondrins
|
|
KR102743950B1
(ko)
|
2015-05-07 |
2024-12-18 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
할리콘드린 마크롤라이드의 합성에 유용한 마크로고리화 반응 및 중간체 및 기타 단편
|
|
WO2016182850A1
(en)
|
2015-05-08 |
2016-11-17 |
Albany Molecular Research, Inc. |
Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
|
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
|
JP6553726B2
(ja)
|
2015-08-20 |
2019-07-31 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
EP3413887B1
(en)
*
|
2016-02-12 |
2021-04-07 |
Eisai R&D Management Co., Ltd. |
Intermediates in the synthesis of eribulin and related methods of synthesis
|
|
US12029724B2
(en)
|
2016-04-28 |
2024-07-09 |
Eisai R&D Management Co., Ltd. |
Method for inhibiting tumor growth
|
|
KR20190009326A
(ko)
*
|
2016-05-26 |
2019-01-28 |
닥터 레디스 레보러터리즈 리미티드 |
에리불린 및 그의 중간체의 제조방법
|
|
US11136335B2
(en)
|
2016-06-30 |
2021-10-05 |
Eisai R&D Management Co., Ltd. |
Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
|
|
BR112019007145A2
(pt)
|
2016-10-14 |
2019-07-02 |
Eisai R&D Man Co Ltd |
combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial
|
|
JP6978758B2
(ja)
|
2016-11-11 |
2021-12-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
パラジウム媒介ケトール化
|
|
CN110167536A
(zh)
*
|
2016-11-23 |
2019-08-23 |
雷迪博士实验室有限公司 |
艾日布林及其中间体的制备方法
|
|
KR101880939B1
(ko)
|
2017-01-02 |
2018-08-17 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
KR101991710B1
(ko)
|
2017-12-14 |
2019-06-21 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
JP6920699B2
(ja)
*
|
2017-01-02 |
2021-08-18 |
ヨンスン ファイン ケミカル カンパニー，リミテッド |
エリブリンメシル酸塩の製造中間体及びその製造方法
|
|
CN108341828B
(zh)
*
|
2017-01-24 |
2021-04-06 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
|
CN108341738B
(zh)
*
|
2017-01-24 |
2022-10-21 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
|
JP6581320B2
(ja)
|
2017-02-08 |
2019-09-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
US9938288B1
(en)
|
2017-04-05 |
2018-04-10 |
President And Fellows Of Harvard College |
Macrocyclic compound and uses thereof
|
|
ES2931533T3
(es)
|
2017-04-05 |
2022-12-30 |
Harvard College |
Compuesto macrocíclico y usos del mismo
|
|
EP3624800A4
(en)
|
2017-05-16 |
2021-02-17 |
Eisai R&D Management Co., Ltd. |
TREATMENT OF HEPATOCELLULAR CARCINOMA
|
|
HUE061306T2
(hu)
|
2017-07-06 |
2023-06-28 |
Harvard College |
Halikondrinok szintézise
|
|
US11498892B2
(en)
|
2017-07-06 |
2022-11-15 |
President And Fellows Of Harvard College |
Fe/Cu-mediated ketone synthesis
|
|
US20190046513A1
(en)
|
2017-08-10 |
2019-02-14 |
Huya Bioscience International, Llc |
Combination therapies of hdac inhibitors and tubulin inhibitors
|
|
CN109694379B
(zh)
*
|
2017-10-24 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的中间体及其制备方法
|
|
JP6967811B2
(ja)
*
|
2017-11-09 |
2021-11-17 |
ヨンスン ファイン ケミカル カンパニー，リミテッド |
エリブリンメシル酸塩の製造中間体及びその製造方法
|
|
CN111566113B
(zh)
|
2017-11-15 |
2024-01-09 |
哈佛大学的校长及成员们 |
大环化合物及其用途
|
|
US11419856B2
(en)
|
2017-11-20 |
2022-08-23 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
|
US11008296B2
(en)
|
2017-11-21 |
2021-05-18 |
Natco Pharma Limited |
Intermediates for the preparation of eribulin thereof
|
|
SG11202005548WA
(en)
|
2018-01-03 |
2020-07-29 |
Eisai R&D Man Co Ltd |
Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
|
|
WO2019211877A1
(en)
|
2018-05-03 |
2019-11-07 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin b
|
|
WO2020008382A1
(en)
*
|
2018-07-04 |
2020-01-09 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
|
JP2021532102A
(ja)
*
|
2018-07-20 |
2021-11-25 |
ドクター レディズ ラボラトリーズ リミテッド |
エリブリンおよびその中間体の調製のための精製プロセス
|
|
EP3864011A4
(en)
*
|
2018-10-09 |
2022-06-29 |
Dr. Reddy's Laboratories Ltd. |
Process for preparation of eribulin and intermediates thereof
|
|
US12522611B2
(en)
*
|
2018-11-28 |
2026-01-13 |
Natco Pharma Limited |
Process for the preparation of high pure Eribulin and its Mesylate salt
|
|
MX2021007562A
(es)
|
2018-12-20 |
2021-09-28 |
Auransa Inc |
Analogos de pentamidina y usos para estos.
|
|
US11447499B2
(en)
|
2019-06-14 |
2022-09-20 |
Rk Pharma Inc. |
Process for the preparation of eribulin mesylate intermediate
|
|
JP7574232B2
(ja)
|
2019-06-21 |
2024-10-28 |
カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ |
ホモプロパルギルアルコールを調製するための化学酵素的プロセス
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
JP7657213B2
(ja)
|
2019-11-07 |
2025-04-04 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法
|
|
CN113135876B
(zh)
*
|
2020-01-16 |
2024-05-17 |
南通诺泰生物医药技术有限公司 |
艾日布林及其中间体的制备方法
|
|
CN118949063A
(zh)
*
|
2020-01-22 |
2024-11-15 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
|
|
KR102377262B1
(ko)
|
2020-05-11 |
2022-03-22 |
연성정밀화학(주) |
결정성 에리불린 염
|
|
IL279168B
(en)
*
|
2020-12-02 |
2022-04-01 |
Finetech Pharmaceutical Ltd |
A process for the preparation of eribulin
|
|
CN113354659B
(zh)
|
2021-06-08 |
2022-04-08 |
江苏慧聚药业股份有限公司 |
甲磺酸艾日布林的合成
|
|
AU2022316425A1
(en)
*
|
2021-07-22 |
2024-02-01 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Drug conjugate of eribulin derivative
|
|
WO2023212746A2
(en)
*
|
2022-04-30 |
2023-11-02 |
William Marsh Rice University |
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
|
|
KR20250133788A
(ko)
*
|
2023-01-17 |
2025-09-08 |
시스트이뮨, 인코포레이티드 |
에리불린 약물 접합체
|
|
EP4725969A1
(en)
|
2023-06-09 |
2026-04-15 |
Latticon (Suzhou) Biopharmaceuticals Co., Ltd. |
Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
|
|
CN118834221B
(zh)
*
|
2023-08-08 |
2025-10-21 |
浙江星月药物科技有限公司 |
一种软海绵素b类似物
|
|
TW202518024A
(zh)
|
2023-10-13 |
2025-05-01 |
日商衛材R&D企管股份有限公司 |
抗體－藥物軛合物代謝物
|
|
WO2025106586A1
(en)
*
|
2023-11-13 |
2025-05-22 |
Luxvitae Therapeutics Inc. |
Macrocyclic ketone compounds and applications thereof
|
|
WO2025228172A1
(zh)
*
|
2024-04-28 |
2025-11-06 |
上海拓济医药有限责任公司 |
艾日布林衍生物及其抗体药物偶联物和医药用途
|